Taiwan Liposome + Yung Shin Pharmaceutical National Team, Ampholipad (amphotericin B liposome) made an emergency medicine aid to India

On May 25th, Taiwan Liposome announced that its antifungal drug, Ampholipad (amphotericin B liposome), has received a drug license from India. The drug will be immediately imported into India for its approved use and indications, addressing the urgent shortage of liposomal amphotericin B in the country.

The COVID-19 pandemic has been escalating in India recently, with the number of confirmed cases remaining high. Cases of COVID-19 associated mucormycosis (CAM) have also surged. COVID-19 associated mucormycosis is a serious and life-threatening fungal infection, affecting 30% of diabetic or immunocompromised patients with COVID-19.

"Ampholipad (amphotericin B liposome)," manufactured and sold by Yung Shin Pharmaceutical under PIC/S GMP certification, is the first and only complex generic drug to achieve bioequivalence with the original drug, AmBisome. It is crucial for India to respond to this urgent need. Taiwan Liposome will work with Yung Shin Pharmaceutical to ensure that Ampholipad is available to patients for early treatment, suppressing the sudden onset of Mucormycosis and reducing mortality.

After the launch of Ampholipad, the company has implemented scale-up and post-approval changes (SUPAC), and has actively expanded into overseas markets. Currently, the annual production capacity has exceeded one million units, meeting the growing global market demand.